

Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HF43E79A410EN.html>

Date: April 2020

Pages: 69

Price: US\$ 2,000.00 (Single User License)

ID: HF43E79A410EN

Abstracts

Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.

Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 7, 7, 2, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Haemophilus influenzae Type B Infections - Overview
- Haemophilus influenzae Type B Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Haemophilus influenzae Type B Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Route of Administration
- Assessment by Molecule Type
- Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Biken Co Ltd
- Biological E Ltd
- Cadila Healthcare Ltd
- CanSino Biologics Inc
- Chongqing Zhifei Biological Products Co Ltd
- GlaxoSmithKline Plc
- Hilleman Laboratories Pvt Ltd
- KM Biologics Co Ltd
- LG Chem Ltd
- Liaoning Chengda Co., Ltd.
- Novo Medi Sciences Pvt Ltd
- Olymvax Biopharmaceuticals Inc
- Panacea Biotec Ltd
- Sanofi Pasteur SA
- Serum Institute of India Ltd
- Shantha Biotechnics Pvt Ltd
- Tuck-More Biotechnology Co Ltd
- Vaxxilon AG
- Yisheng Biopharma Co Ltd
- Haemophilus influenzae Type B Infections - Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis)

(acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus)
(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis
(acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio +
tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis +
tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus)
(tetraivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal
[serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell)
+ poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description**Mechanism Of Action****R&D Progress**

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile

Product Description**Mechanism Of Action****R&D Progress**

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile

Product Description**Mechanism Of Action****R&D Progress**

(diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile

Product Description**Mechanism Of Action****R&D Progress**

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile

Product Description**Mechanism Of Action****R&D Progress**

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description**Mechanism Of Action****R&D Progress**

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile

Product Description**Mechanism Of Action****R&D Progress**

(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile

Product Description

Mechanism Of Action
R&D Progress
BK-1310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
haemophilus influenza B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-Hib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae Type B Infections - Dormant Projects

Haemophilus influenzae Type B Infections - Discontinued Products

Haemophilus influenzae Type B Infections - Product Development Milestones

Featured News & Press Releases

Jan 07, 2019: Biomedical Sciences researcher gets \$3.26 million grant to develop universal flu vaccine

Jun 24, 2015: Hilleman Laboratories' preclinical trial report on Hib vaccine offers hope to millions of children

Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5

Nov 10, 2014: Shantha's Pentavalent Pediatric Vaccine launched in India

May 05, 2014: Shantha's Pentavalent Pediatric Vaccine prequalified by World Health Organization

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Haemophilus influenzae Type B Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Biken Co Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Biological E Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Cadila Healthcare Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by CanSino Biologics Inc, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by GlaxoSmithKline Plc, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by KM Biologics Co Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by LG Chem Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Liaoning Chengda Co., Ltd., H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Serum Institute of India Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Shantha Biotechnics Pvt Ltd,

H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Tuck-More Biotechnology Co Ltd, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Vaxxilon AG, H1 2020

Haemophilus influenzae Type B Infections - Pipeline by Yisheng Biopharma Co Ltd, H1 2020

Haemophilus influenzae Type B Infections - Dormant Projects, H1 2020

Haemophilus influenzae Type B Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020

Haemophilus influenzae Type B Infections - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Haemophilus influenzae Type B Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Beijing Minhai Biotechnology Co Ltd

Biken Co Ltd

Biological E Ltd

Cadila Healthcare Ltd

CanSino Biologics Inc

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

Hilleman Laboratories Pvt Ltd

KM Biologics Co Ltd

LG Chem Ltd

Liaoning Chengda Co., Ltd.

Novo Medi Sciences Pvt Ltd

Olymvax Biopharmaceuticals Inc

Panacea Biotec Ltd

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Tuck-More Biotechnology Co Ltd

Vaxxilon AG

Yisheng Biopharma Co Ltd

I would like to order

Product name: Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HF43E79A410EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HF43E79A410EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970